21 Recruiting Non-Hodgkin's Lymphoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by Study Phase
Top Interventions for Non-Hodgkin's Lymphoma
Top Recruiting Non-Hodgkin's Lymphoma Studies
🔵 Active, Not Recruiting Phase1 📋 Clinical Research Protocol
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
📍 Houston Methodist Hospital — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Early Phase1 💊 Investigational Drug / Biologic
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
📍 University of Michigan — Ann Arbor, Michigan
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
📍 Carolina BioOncology Institute /ID# 265259 — Huntersville, North Carolina
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
📍 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔ 🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔